title: Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study.
authors.affiliation: University of New Mexico, Albuquerque.
authors.forename: R P
authors.initials: RP
authors.lastname: Whitehead
authors.forename: K J
authors.initials: KJ
authors.lastname: Kopecky
authors.forename: M K
authors.initials: MK
authors.lastname: Samson
authors.forename: J J
authors.initials: JJ
authors.lastname: Costanzi
authors.forename: R B
authors.initials: RB
authors.lastname: Natale
authors.forename: L G
authors.initials: LG
authors.lastname: Feun
authors.forename: E M
authors.initials: EM
authors.lastname: Hersh
authors.forename: J J
authors.initials: JJ
authors.lastname: Rinehart
mesh_terms: D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins